Jan A. Burger

2.2k citations

26 papers · 1.6k indexed · 1 hit paper · h-index 10

Co-authors: Nathan J. Zvaifler Nobuhiro Tsukada Thomas J. Kipps Christopher Edwards Ravinder N. Maini Gill Adams Michael J. Keating Gary S. Firestein
Topics: Chronic Lymphocytic Leukemia Research (20 papers)Chronic Myeloid Leukemia Treatments (8 papers)Acute Lymphoblastic Leukemia research (8 papers)
Cited by: Genetics Hematology Immunology
Journals: Journal of Clinical Investigation Blood Nature Cell Biology
Partner nations: United States Italy Canada

In The Last Decade

Jan A. Burger

25 papers receiving 1.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Mesenchymal precursor cells in the blood of normal individuals

2000 561 citations Nathan J. Zvaifler, Gill Adams et al. Arthritis Research & Therapy profile →

Peers

Countries citing papers authored by Jan A. Burger

Since Specialization

Citations

This map shows the geographic impact of Jan A. Burger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jan A. Burger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jan A. Burger more than expected).

Fields of papers citing papers by Jan A. Burger

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jan A. Burger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jan A. Burger. The network helps show where Jan A. Burger may publish in the future.

Co-authorship network of co-authors of Jan A. Burger

This figure shows the co-authorship network connecting the top 25 collaborators of Jan A. Burger. A scholar is included among the top collaborators of Jan A. Burger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jan A. Burger. Jan A. Burger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Treatment with First-Line Ibrutinib Improves Overall Survival in Patients with Chronic Lymphocytic Leukemia (CLL) and High-Risk Genomic Features to Rates Approximating an Age-Matched US Population: Pooled Analysis of Phase 3 Trials with 10 Years of Follow-up 2024 ·Blood ·Jan A. Burger,Neil E. Kay,John N. Allan,Paul M. Barr,Jacqueline C. Barrientos,Carolyn Owen,Victoria Wang,Hsin-Hui Huang,Lynne Neumayr,(unknown),(unknown),Shefali Mody,Paolo Ghia,Tait D. Shanafelt	0
2	First‐line ibrutinib treatment in patients with chronic lymphocytic leukemia is associated with overall survival rates similar to those of an age‐matched general population: A pooled post hoc analysis 2024 ·HemaSphere ·Paolo Ghia,Carolyn Owen,John N. Allan,Jacqueline C. Barrientos,Paul M. Barr,Chunxue Shi,(unknown),(unknown),(unknown),Jan A. Burger	7
3	A Phase II Study of Inotuzumab Ozogamicin for the Treatment of Measurable Residual Disease-Positive B-Cell Acute Lymphoblastic Leukemia 2022 ·Blood ·Jayastu Senapati,Nicholas J. Short,Yesid Alvarado,Jan A. Burger,Nitin Jain,Marina Konopleva,Farhad Ravandi,Courtney D. DiNardo,Lucia Masárová,Koji Sasaki,Philip A. Thompson,Alessandra Ferrajoli,Jovitta Jacob,(unknown),Anna Milton,Christopher Loiselle,Rebecca Garris,Hagop Kantarjian,Elias Jabbour	5
4	Early Treatment with Ofatumumab in Patients with High-Risk CLL 2022 ·Blood ·(unknown),Michael J. Keating,Alessandra Ferrajoli,Nitin Jain,Maro Ohanian,Naveen Pemmaraju,Courtney D. DiNardo,Marina Konopleva,Tapan M. Kadia,Susan O’Brien,Zeev Estrov,Deborah A. Thomas,Jan A. Burger,Philip A. Thompson,William G. Wierda	3
5	Initiating First-Line (1L) Ibrutinib (Ibr) in Patients (pts) with Chronic Lymphocytic Leukemia (CLL) Improves Overall Survival (OS) Outcomes to Rates Approximating an Age-Matched Population of ≥65 Years 2022 ·Blood ·Paolo Ghia,Carolyn Owen,Jacqueline C. Barrientos,Paul M. Barr,Anthony R. Mato,Chunxue Shi,Anita Szőke,(unknown),(unknown),Jan A. Burger	7
6	Incorporation of Nelarabine (NEL), Pegylated Asparaginase (PEG) and Venetoclax (VEN) in the Frontline Therapy of Adult Patients with T-Acute Lymphoblastic Leukemia/T-Lymphoblastic Lymphoma (T-ALL/LBL) 2022 ·Blood ·(unknown),Hagop M. Kantarjian,Elias Jabbour,Gautam Borthakur,Marina Konopleva,William G. Wierda,Jan A. Burger,Ghayas C. Issa,Abhishek Maiti,(unknown),Mary Ann Kelly,Rebecca Garris,Alessandra Ferrajoli,Guillermo Garcia‐Manero,Yesid Alvarado,Nicholas J. Short,Nitin Jain,Farhad Ravandi	3
7	Safety and Efficacy of Blinatumomab in Combination with a Tyrosine Kinase Inhibitor for the Treatment of Relapsed Philadelphia Chromosome-Positive Leukemia 2017 ·Clinical Lymphoma Myeloma & Leukemia ·Rita Assi,Hagop M. Kantarjian,Nicholas J. Short,Naval Daver,Koichi Takahashi,Guillermo Garcia‐Manero,Courtney D. DiNardo,(unknown),Jan A. Burger,Nitin Jain,William G. Wierda,(unknown),Marina Konopleva,Elias Jabbour	4
8	Three Newly Approved Drugs for Chronic Lymphocytic Leukemia: Incorporating Ibrutinib, Idelalisib, and Obinutuzumab into Clinical Practice 2015 ·Clinical Lymphoma Myeloma & Leukemia ·David Sanford,William G. Wierda,Jan A. Burger,Michael J. Keating,Susan O’Brien	19
9	The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia 2015 ·Blood ·Jennifer R. Brown,Jacqueline C. Barrientos,Paul M. Barr,Ian W. Flinn,Jan A. Burger,(unknown),Fong Clow,Danelle F. James,Thorsten Graef,Jonathan W. Friedberg,R. Kanti,Susan O’Brien	91
10	Kinetics of CLL cells in tissues and blood during therapy with the BTK inhibitor ibrutinib 2014 ·Blood ·Dominik Wodarz,Naveen Garg,Natalia L. Komarova,Ohad Benjamini,Michael J. Keating,William G. Wierda,Hagop Kantarjian,Danelle F. James,Susan O’Brien,Jan A. Burger	78
11	Incidence and Outcome In Adults With Acute Lymphoblastic Leukemia With Primary Central Nervous System Involvement 2013 ·Blood ·Muhamed Baljević,Hagop M. Kantarjian,Deborah A. Thomas,Michael Rytting,(unknown),Gautam Borthakur,Jan A. Burger,Farhad Ravandi,Elias Jabbour,Marina Konopleva,Sherry Pierce,Mark Brandt,Susan O’Brien,Jörge E. Cortes	1
12	Kinetics Of Chronic Lymphocytic Leukemia Cells In Tissues and Blood During Therapy With The BTK Inhibitor Ibrutinib 2013 ·Blood ·Dominik Wodarz,Naveen Garg,Natalia L. Komarova,Ohad Benjamini,Michael J. Keating,William G. Wierda,Hagop M. Kantarjian,Danelle F. James,Susan O’Brien,Jan A. Burger	1
13	Stromal control of cystine metabolism promotes cancer cell survival in chronic lymphocytic leukaemia 2012 ·Nature Cell Biology ·Wan Zhang,Dunyaporn Trachootham,Jinyun Liu,Gang Chen,Hélène Pelicano,Celia Garcı́a-Prieto,Weiqin Lu,Jan A. Burger,Carlo M. Croce,William Plunkett,Michael J. Keating,Peng Huang	280
14	Targeting the microenvironment in chronic lymphocytic leukemia is changing the therapeutic landscape 2012 ·Current Opinion in Oncology ·Jan A. Burger	55
15	Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndrome 2012 ·Blood ·Naval Daver,Hagop M. Kantarjian,Guillermo Garcia‐Manero,Zeev Estrov,Marina Konopleva,Jan A. Burger,Susan O’Brien,Alessandra Ferrajoli,Srđan Verstovšek,Tapan M. Kadia,Elias Jabbour,Stefan Faderl,(unknown),Naveen Pemmaraju,Sherry Pierce,Jörge E. Cortes,Gautam Borthakur	4
16	Deletion 11q Abnormality in Patients with Chronic Lymphocytic Leukemia (CLL) May Not Have Poor Clinical Outcomes and Bulky Disease (clinical and radiological) At Presentation – Clinical Characteristics of (n=172) Previously Untreated Patients with CLL and del11q Cytogenetic Abnormality. 2012 ·Blood ·Preetesh Jain,Long Trinh,Ohad Benjamini,Susan Lerner,Xuemei Wang,Alessandra Ferrajoli,Jan A. Burger,Zeev Estrov,William G. Wierda,Hagop M. Kantarjian,Susan O’Brien,Lynne V. Abruzzo,Michael J. Keating	1
17	Phase II Study of Combination of hyperCVAD with Dasatinib in Frontline Therapy of Patients with Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL) 2008 ·Blood ·Farhad Ravandi,Deborah Thomas,Hagop Kantarjian,Stefan Faderl,Charles Koller,Samuel Dara,Rebecca Garris,Partow Kebriaei,Gautam Borthakur,William G. Wierda,Jan A. Burger,Jörge E. Cortes,Susan O’Brien	5
18	Fledgling prognostic markers in CLL 2007 ·Blood ·Jan A. Burger	1
19	Fibroblast-like synoviocytes support B-cell pseudoemperipolesis via a stromal cell–derived factor-1– and CD106 (VCAM-1)–dependent mechanism 2001 ·Journal of Clinical Investigation ·Jan A. Burger,Nathan J. Zvaifler,Nobuhiro Tsukada,Gary S. Firestein,Thomas J. Kipps	153
20	Mesenchymal precursor cells in the blood of normal individualsbreakdown → 2000 ·Arthritis Research & Therapy ·Nathan J. Zvaifler,(unknown),Gill Adams,Christopher Edwards,(unknown),Jan A. Burger,Ravinder N. Maini	561

About Jan A. Burger

Jan A. Burger is a scholar working on Genetics, Hematology and Pathology and Forensic Medicine, having authored 26 papers that have together received 1.6k indexed citations. Recurring topics across this work include Chronic Lymphocytic Leukemia Research (20 papers), Chronic Myeloid Leukemia Treatments (8 papers) and Acute Lymphoblastic Leukemia research (8 papers). The work is most often cited by research in Genetics (956 citations), Hematology (237 citations) and Immunology (409 citations). Jan A. Burger has collaborated with scholars based in United States, Italy and Canada. Frequent co-authors include Nathan J. Zvaifler, Nobuhiro Tsukada, Thomas J. Kipps, Christopher Edwards, Ravinder N. Maini, Gill Adams, Michael J. Keating, Gary S. Firestein, Peng Huang and William Plunkett. Their work appears in journals such as Journal of Clinical Investigation, Blood and Nature Cell Biology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact